 - full-dose anticoagulants with PT INR 1.5 eligible provided that: a patient is therapeutic on stable dose of warfarin or low molecular weight heparin; b patients on warfarin, the upper target for INR is 3; c no active bleedingpathological condition carrying high bleeding risk 